Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    Only $11.99/month after trial. Cancel anytime.

    Summary of Evan Hughes's The Hard Sell
    Summary of Evan Hughes's The Hard Sell
    Summary of Evan Hughes's The Hard Sell
    Ebook47 pages20 minutes

    Summary of Evan Hughes's The Hard Sell

    By IRB Media

    ()

    Read preview

    About this ebook

    Please note: This is a companion version & not the original book. Book Preview:

    #1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.

    #2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.

    #3 Kapoor’s company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.

    #4 After the acquisition, Lyphomed’s value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.

    LanguageEnglish
    PublisherIRB Media
    Release dateJul 17, 2022
    ISBN9798822547421
    Summary of Evan Hughes's The Hard Sell
    Author

    IRB Media

    With IRB books, you can get the key takeaways and analysis of a book in 15 minutes. We read every chapter, identify the key takeaways and analyze them for your convenience.

    Read more from Irb Media

    Related to Summary of Evan Hughes's The Hard Sell

    Related ebooks

    Biography & Memoir For You

    View More
    View More

    Related podcast episodes

    Related articles

    • Article

      And Now, Your Nominees For Worst Biopharma CEO Of 2019. Let The Voting Begin!

      Dec 17, 2019

      I feel a touch of shame admitting that I enjoy compiling my annual list of the worst CEOs in biopharma, more than that other list of best CEOs. Reporters love bad news, what can I say? I digress. Here are the CEOs who screwed up bad enough to rise to

      4 min read

    • Article

      Kanabo: How Childhood Migraines Inspired The Founder Of Cannabis Firm At Centre Of Share Price Frenzy

      Feb 19, 2021

      The blockbuster launch of Kanabo paves the way for London to become a financial hub for the fast-growing medical cannabis sector, its founder said today. Shares in the Israel-based company, which makes a vaping pen to dispense regulated doses of medi

      5 min read

    • Article

      Fentanyl Executive John Kapoor’s Conviction Is Good News For Holding Corporations Accountable

      May 2, 2019

      A jury didn't buy Kapoor’s defense that he did not know what his lieutenants were doing. That’s good news for anyone hoping we can discourage other pharma entrepreneurs from lining…

      2 min read

    • Article

      Betting On Bausch With The Big Guys

      Jun 11, 2021

      a lot of people talk about the “smart money”. “Follow the smart money” they say, or “the smart money was buying while the market sold off”, and all sorts of things that basically allude to those who act against the conventional wisdom of the masses a

      4 min read

    • Article

      COURTING Cipla

      Oct 13, 2023

      COURTING Cipla
      8 min read

    • Article

      The Pfizer-Mylan Deal Is Not Quite As It Appears

      Jul 29, 2019

      The early reaction to the Pfizer-Mylan deal is that it’s great for Mylan but maybe not so amazing for Pfizer. A close look at the deal may lead to a…

      3 min read

    • Article

      And Now, Your Nominees For Worst Biopharma CEO Of 2018. Let The Voting Begin!

      Dec 13, 2018

      Yesterday, I lauded the best biopharma CEOs of 2018. Today, I give a side-eye glance to the worst. To land on this ignominious list, biopharma CEOs had to screw up so badly over the past 12 months to set off my outrage alarm. Serial incompetence is a

      3 min read

    • Article

      Move Over Tech: Marijuana Stocks Are the New Star

      Jun 20, 2018

      Cannabis is just a plant - a controversial plant, but a plant nonetheless. However, this humble plant increasingly looks to be at the heart of the next great investment: marijuana stocks. On the federal level, marijuana, hemp and all types of cannabi

      5 min read

    • Article

      Pfizer’s Covid Moon Shot

      Jul 30, 2020

      Pfizer’s Covid Moon Shot
      11 min read

    • Article

      2019 Top 25 Innovators

      Jan 3, 2020

      Cultivation, technology, research, business, advocacy, social justice, legislation: there are so many aspects that build up the cannabis industry. Each year, people from all over are working to advance cannabis in their own respective ways, resulting

      7 min read

    • Article

      Introducing the Nominees for Best Biopharma CEO of 2017. Vote for Your Favorite!

      Dec 11, 2017

      The criteria for determining the best biopharma CEO of 2017 was exceptionally high, which makes the nominees on this list all the more exceptional.

      2 min read

    • Article

      Crash And Burn: Why Three Biotechs Failed In 2018

      Dec 24, 2018

      There is an appointed time for everything — including in biotech. There is a time to start a company, a time to wind it down, a time to go public, and a time to delist the stock. For every hopeful biotech toiling for decades before finally realizing

      5 min read

    • Article

      Kapoor Certainly Deserves To Go To Jail, But So Do Some Other Pharma Execs

      May 2, 2019

      Hang ’em high. There is no getting around this age-old imagery. Insys Therapeutics founder John Kapoor and his former gang members at the disgraced drug maker should get the maximum sentences for their shameful roles in helping to foment an opioid cr

      2 min read

    • Article

      Former Novartis Exec Wants To Repurpose Generic Drugs To Fight Covid-19

      Apr 7, 2020

      As Covid-19 sweeps the globe, a growing number of efforts are underway to quickly research and develop treatments and vaccines. Yet much of the work is disjointed and widespread access to any medical product is uncertain. One idea, suggested by Costa

      5 min read

    • Article

      Here Are The Nominees For Best Biopharma CEO Of 2019. Vote For Your Favorite!

      Dec 16, 2019

      Here are the nominees for best biopharma CEO of 2019. Vote for your favorite — and get ready for the nominees for worst, coming tomorrow.

      4 min read

    • Article

      The Best Trades In History… Carl Icahn’s Alchemical Touch

      Jul 7, 2023

      Carl Icahn was born in New York City in 1936. After studying at Princeton, he enrolled briefly at the New York University School of Medicine before dropping out to join the army. In 1961 he joined Dreyfus & Co as a stockbroker and by 1968 he had put

      1 min read

    • Article

      The High Times 1oo

      Apr 9, 2019

      The High Times 1oo
      26 min read

    • Article

      The Billion-Dollar Gamble: Biotech CEO Takes a Risky Second Shot at an Alzheimer’s Drug

      Sep 7, 2017

      Dr. David Hung's first bid to develop an Alzheimer's drug flopped spectacularly. Now he's taking another risky shot, with results to be unveiled this month.

      8 min read

    Related categories

    Reviews for Summary of Evan Hughes's The Hard Sell

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Summary of Evan Hughes's The Hard Sell - IRB Media

      Insights on Evan Hughes's The Hard Sell

      Contents

      Insights from Chapter 1

      Insights from Chapter 2

      Insights from Chapter 3

      Insights from Chapter 4

      Insights from Chapter 5

      Insights from Chapter 6

      Insights from Chapter 7

      Insights from Chapter 8

      Insights from Chapter 9

      Insights from Chapter 10

      Insights from Chapter 11

      Insights from Chapter 12

      Insights from Chapter 13

      Insights from Chapter 14

      Insights from Chapter 15

      Insights from Chapter 16

      Insights from Chapter 17

      Insights from Chapter 18

      Insights from Chapter 19

      Insights from Chapter 20

      Insights from Chapter 21

      Insights from Chapter 22

      Insights from Chapter 1

      #1

      Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.

      #2

      Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.

      #3

      Kapoor’s company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.

      #4

      After the acquisition, Lyphomed’s value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.

      #5

      After the meeting, Babich felt he had been quietly passed over for the job. A second interview was followed by another lengthy unexplained silence. When Babich finally got a job offer, it came in the form of a letter in

      Enjoying the preview?
      Page 1 of 1